GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR) has obtained regulatory approval from the Chinese SFDA (State Food and Drug Administration) for aspiration needles and micropipettes used for infertility treatment (IVF). With the previous approved culture media portfolio Vitrolife can now offer a full line of high quality products for IVF-treatment and reassert its leading position in the fast growing Chinese market.
